CSBR (Champions Oncology) GF Value : $6.07 (As of Jun. 22, 2025)

View and export this data going back to 1994. Start your Free Trial

What is Champions Oncology GF Value?

As of today (2025-06-22), Champions Oncology's share price is $8.29. Champions Oncology's GF Value is $6.07. Therefore, Champions Oncology's Price-to-GF-Value for today is 1.37. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Champions Oncology is Significantly Overvalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Champions Oncology (NAS:CSBR) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (1)
Possible Value Trap, Think Twice	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (2)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (2)	Predictable High Quality Companies which are Significantly Undervalued

(1) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(2) A sufficient margin of safety exists only when the stock is undervalued.

Possible Value Trap, Think Twice companies are those that appear significantly undervalued based on their Price-to-GF-Value ratio, but whose fundamentals show signs of weakness.

Indicators that a company may be a value trap include:

    * Deteriorating Financial Health: A low Altman Z-scores indicates a higher risk of bankruptcy, or a low Piotroski F-Score.
    * Earnings Manipulation: A high Beneish M-score indicates potential earnings manipulation, raising concerns about the reliability of reported financials.
    * Stagnant or Declining Growth: Lack of revenue or earnings growth, or a recent slowdown, may signal limited future prospects.

Investors should conduct thorough due diligence, examining financial statements and growth indicators, to avoid falling into value traps.

Champions Oncology's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	8.29	/	6.07
	=	1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology GF Value Related Terms

Thank you for viewing the detailed overview of Champions Oncology's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Champions Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website

https://www.championsoncology.com

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Executives

Daniel Newman Mendelson	director	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris	director, officer: President	855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld	director	ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp.	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman	10 percent owner	ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman	director, officer: Chief Executive Officer	COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins	10 percent owner
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Harry R Weller	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815